A Phase 2/3 Efficacy and Safety Study of Ravulizumab in Pediatric Patients with NMOSD
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
What was tested
Treatment tested
- Ravulizumab
Complement C5 inhibitor
What it measured
Main measures
- The change from baseline in the annualized relapse rate (ARR)
Relapses
Other measures (1)
Primary treatment period:
Loading reviews and guidelines…
Related trials
- BEST-NMOSD
Phase 4 · Recruiting
Still running
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and…
Phase 3 · Recruiting
Still running
- ETA/PETA-NMOSD
Phase 4 · Recruiting
Still running
- ELITE
Phase 3 · Recruiting
Still running
- EASE-NMO
Phase 2 · Running, not recruiting
Still running
- EASE-NMO
Phase 2 · Withdrawn
Stopped early
History
- In scope changed from true to false
Started
Feb 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error